Abstract
Growth Velocity (GV) In response to recombinant GH Rx was analyzed using KIGS data base. IGHD was based on classical criteria : short stature, slow growth velocity; GH peak response at 2 provocative tests below 10 ng/ml; thyroid and adrenal status were based on conventional hormonal evaluation (local assays). Organic GHD was ruled out by brain imaging. 1256 prepubertal IGHD GH treated patients in KIGS data base were analysed. At start of Rx median chronological Age (CA) was 7.3 years, median height Standart Deviation Score (SDS) was - 2.7. Median number of injections was 6/week and medians GV were 8.2 & 6.9 cm/year during Rx year 1 & 2 respectively. Out of ten potential predictors, multiple regression analysis resulted in a five predictors model for growth response to Rx : Target Height (SDS), Height SDS for CA, CA at start, GH Dose & GH injection Frequency (R-square = 0.37). The effect of GH dose at 3 versus 7 injections/week according to CA are shown in the figure. The 2 predictors not shown are fixed at their median value. Conclusions :These data provide useful information for optimizing GH treatment in IGHD and predicting growth response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
